Related Experiment Video
Updated: Aug 2, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Sample Size Calculation for Clinical Trials of Medical Decision Support Systems with Binary Outcome
1Professor, Department of Medical Cybernetics and Informatics; Pirogov Russian National Research Medical University, 1 Ostrovityanova St., Moscow, 117997, Russia; Professor, Department of Endocrinology, Institute for Higher Education and Additional Professional Training; Endocrinology Research Centre, 11 Dmitriya Ulyanova St., Moscow, 117292, Russia; Leading Researcher, Sector of Dynamic Neural Networks, Department of Neuroinformatics, Center for Optical-Neuron Technologies; Federal State Institution "Scientific Research Institute for System Analysis of the Russian Academy of Sciences", 36/1 Nakhimovsky Prospect, Moscow, 117218, Russia; Chief Researcher, Laboratory of Evidence-Based Medicine and Biostatistics; Mental Health Research Center, 34 Kashirskoye Shosse, Moscow, 115522, Russia.
Abstract:
Currently, software products for use in medicine are actively developed. Among them, the dominant share belongs to clinical decision support systems (CDSS), which can be intelligent (based on mathematical models obtained by machine learning methods or other artificial intelligence technologies) or non-intelligent. For the state registration of CDSSs as software medical products, clinical trials are required, and the protocol of trial is developed jointly by the developer and an authorized medical organization. One of the mandatory components of the protocol is the calculation of the sample size. This article discusses the calculation of the sample size for the most common case, the binary outcome in diagnostic/screening and predictive systems. For diagnostic/screening models, cases of a non-comparative study, comparative study with testing of the superiority hypothesis, comparative study with testing of a hypothesis of non-inferiority in cross-sectional studies are considered. For predictive models, cases of randomized controlled trials of the complex intervention "prediction + prediction-dependent patient management" with testing of the hypothesis of superiority and non-inferiority are considered. It is emphasized that representativeness of the sample and other design components are no less important in clinical trials than sample size. They are even more important since systematic biases in clinical trials are primary, and even the most sophisticated statistical analysis cannot compensate for design defects. The reduction of clinical trials to external validation of models (i.e. evaluation of accuracy metrics on external data) seems completely unreasonable. It is recommended to perform clinical trials with the design adequate to the tasks, so that further clinical and economic analysis and comprehensive assessment of medical technologies are possible. The sample size calculation methods described in the article can potentially be applied to a wider range of medical devices.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Related Concept Videos
Sample Size Calculation
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Odds Ratio
Margin of Error
Hazard Ratio
For example, in a clinical trial...